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ARTICLE
Prevalence and detection of low-allele-fraction
variants in clinical cancer samples
Hyun-Tae Shin1,2, Yoon-La Choi2,3, Jae Won Yun1,2, Nayoung K.D. Kim1, Sook-Young Kim1, Hyo Jeong Jeon1,
Jae-Yong Nam1,2, Chung Lee1,2, Daeun Ryu1,2, Sang Cheol Kim1, Kyunghee Park1, Eunjin Lee1, Joon Seol Bae1,
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Woo Yong Lee5, Bo Young Oh5,6, Yeon Hee Park4, Jeong Eon Lee5, Kwang Hyuk Lee7, Hee Cheol Kim5,
Kyoung-Mee Kim3, Young-Hyuck Im4, Keunchil Park4, Peter J. Park 8 & Woong-Yang Park 1,2,9
Accurate detection of genomic alterations using high-throughput sequencing is an essential
component of precision cancer medicine. We characterize the variant allele fractions (VAFs)
of somatic single nucleotide variants and indels across 5095 clinical samples proﬁled using a
custom panel, CancerSCAN. Our results demonstrate that a signiﬁcant fraction of clinically
actionable variants have low VAFs, often due to low tumor purity and treatment-induced
mutations. The percentages of mutations under 5% VAF across hotspots in EGFR, KRAS,
PIK3CA, and BRAF are 16%, 11%, 12%, and 10%, respectively, with 24% for EGFR T790M and
17% for PIK3CA E545. For clinical relevance, we describe two patients for whom targeted
therapy achieved remission despite low VAF mutations. We also characterize the read depths
necessary to achieve sensitivity and speciﬁcity comparable to current laboratory assays.
These results show that capturing low VAF mutations at hotspots by sufﬁcient sequencing
coverage and carefully tuned algorithms is imperative for a clinical assay.
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Genomic proﬁling of tumors by high-throughput sequen-cing has fueled rapid progress on our understanding ofthe molecular features underlying all steps of carcino-
genesis—tumor initiation, progression, response to treatment,
and relapse1,2. Sequencing technology continues to advance
quickly, notably with whole-genome sequencing (WGS) becom-
ing more affordable, and ampliﬁcation and sequencing of RNA
and DNA at the single cell level becoming possible3,4. However,
translation of the insights from molecular proﬁling to patient care
has been much slower. Several studies have shown that selection
of therapy based on genomic proﬁling of few hotspot mutations
could lead to prolonged survival for patients5–7. But the repertoire
of drugs available for treatment has not been expanding as rapidly
as our ability to identify the mutation, limiting the usefulness of
whole-exome sequencing (WES) or WGS.
A number of factors are prerequisite for a successful imple-
mentation of a genome-guided therapy selection in routine cancer
care. First, obtaining a representative tumor specimen of sufﬁ-
cient quality for genome proﬁling is an on-going challenge. Given
the heterogeneity of a tumor in an individual8, a full description
of the tumor may require multiple samplings of different geo-
graphic regions, but this is not feasible in the clinic. Proﬁling of
circulating tumor cells offers a promising approach for a non-
invasive and serial characterization, but it is limited to a minority
of tumor types and relies on a less mature technology and
extremely deep sequencing9. Second, a comprehensive proﬁling
of mutations in a tumor is possible but requires multiple assays
and extensive bioinformatic analysis. The assay platform ranges
from full genome coverage (typically at 30–60×) with WGS to
exome-only coverage (typically 100-200×) to narrow genome
coverage (typically at 500–1000×) with panel sequencing. These
platforms offer a trade-off between the depth and breadth of
proﬁling. Sequencing RNA is also an attractive option, as it can be
used to identify single nucleotide variants (SNVs)/insertions and
deletions (indels) and gene fusions from expressed transcripts. All
these assays are complimentary and can be useful for cross-
validating mutations, but performing multiple assays is often
prohibitive due to the cost and the lack of expertise needed for
data analysis. Third, even when a somatic mutation is found,
assessing whether it plays a role as a ‘driver’ rather than a
‘passenger’ is difﬁcult. A variety of resources such a catalog of
previously observed somatic mutations10 and computational tools
for predicting the effect of an observed coding mutation on
protein function exist11,12. However, a large integrated database
of cancer genome proﬁling and clinical data to infer whether a
mutation might be correlated with treatment response is lacking.
At this time, such information is available only for a relatively
small set of hotspot mutations.
As the catalog of hotspot mutations that are associated with
clinical outcome and the drugs that target those mutations con-
tinue to expand, a critical area of improvement is to increase the
sensitivity of detecting known hotspot mutations. Here we focus
on the questions of how reliably we can detect somatic mutations
in cancer using a targeted sequencing panel—especially in com-
parison to the currently available clinical assays—and whether
hard-to-detect mutations that require high sequencing coverage
are clinically relevant. The ﬁrst question is intimately related to
the question of how the variant allele fractions (VAFs) for such
mutations are distributed in a large population of cancer patients,
since it is difﬁcult to assess what the appropriate sequencing
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Fig. 1 Prevalence of point mutations with low variant allele fraction (VAF) in cancer specimens. VAF distributions of the four most frequently mutated
actionable genes in our data: EGFR, KRAS, PIK3CA, and BRAF. Each dot corresponds to a sample, with the violin plot showing the estimated density; the red
vertical dotted lines are at 5, 10, and 20% VAF. 24% of the EGFR T790M, 17% of PIK3CA E545, and 12% of KRAS G12 mutations are below 5%. Two
important non-frameshift indels (indicated by asterisk) are also included for EGFR
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coverage is unless we have the VAF information; the second
question requires curation of treatment response data for a large
number of cases. To address these issues, we have performed
detailed analysis of 5095 clinical cancer samples proﬁled at the
Samsung Medical Center over the past three years. Our analysis
details the observed mutations in a large cohort, describes the
VAF distribution at hotspot mutations, estimates the sequencing
depth necessary to obtain the “limit-of-detection” that is similar
to what is standard for clinical assays, reports the estimated
distribution of tumor purity across the cohort, describes the issues
related to formaldehyde ﬁxed-parafﬁn embedded (FFPE) tissues,
gives examples of cases in which low VAF mutations were used to
select treatment for patients, and compares the progression free
survival data for patients with a low VAF vs high VAF variant
who received targeted therapy.
Results
Sequencing of cancer patients. Over a period of three years, we
sequenced DNA from 5095 patients who could potentially beneﬁt
from a clinical trial if an actionable mutation is discovered. We
utilized a custom-designed panel that covered up to 381 cancer-
related genes curated from the literature (Supplementary Data 1),
as well as the TERT promoter and introns that contain frequent
breakpoints for selected fusion candidates. These selected genes
covered variants associated with the targeted cancer therapies
approved by the US Food and Drug Administration (FDA),
Korean Ministry of Food and Drug Safety (MFDS) or in the
clinical trials at the Precision Oncology Clinic at Samsung
Medical Center. A custom panel offered the ﬂexibility to rapidly
incorporate the relevant candidate variants as new clinical trials
are initiated. About half of the cases were also refractory tumors
with a history of recurrence and/or metastasis (Supplementary
Data 2); nearly half of the samples were formalin-ﬁxed parafﬁn-
embedded (FFPE) tissue samples. Most samples had the mean
coverage of ~900× (Supplementary Data 3), with the coverage at
hotspots well above the mean.
Characterization of mutant allele frequencies at hotspots. After
standard quality control and genome alignment, we identiﬁed
SNVs using a combination of two algorithms, MuTect13 and
LoFreq14. The former implements a Bayesian classiﬁer with
several post-calling ﬁlters to reduce false positives; the latter was
designed speciﬁcally for extremely low VAF variants. We further
designed a ﬁltering step based on a regression model trained on
low VAF variants in normal samples and applied it to somatic
variant calls. The union of the two callers and the additional
ﬁltering step substantially increased the accuracy of the variant
list, according to our tests on simulation data consisting of
mixtures of well-characterized samples at speciﬁed ratios
(More details are in Methods section).
We did not have a paired normal tissue in the majority of the
cases, so we used a set of >400 normal samples with matched
ethnicity to remove germline variants (Methods section). To test
the effectiveness of this ﬁltering process, we sequenced 74 breast
cancer samples along with their paired normals (tumor:
CancerSCAN V1, 83-gene panel at ~900×, normal: WES at
~100×) and examined how the ﬁltering using a panel of normals
compares with using paired normals. We found that the vast
majority (94.5%; 1928 out of 2040) of the germline variants
identiﬁed from paired WES data were removed by the panel of
(unpaired) normals. This is consistent with the recent paper
showing that, with ~400 unrelated genomes for ﬁltering germline
variants, somatic SNVs and indels could be distinguished from
germline ones as efﬁciently as having the matched normals15.
Importantly, we found that the VAFs at many clinically-
important hotspots are often very low across our samples. In
Fig. 1a–d, we show the distribution of VAFs for the four genes
with the highest frequency of SNVs in our data; other genes are
shown in Supplementary Fig. 1. Across the 20 hotspots, EGFR,
KRAS, PIK3CA, and BRAF have 28, 21, 26, and 17% of mutations
under 10%, respectively. The percentages of mutations under 5%
VAF are 16, 11, 12, and 10%, respectively. To give examples of
speciﬁc hotspots, 24% of the EGFR T790M, 17% of PIK3CA E545,
and 12% of KRAS G12 mutations are below 5%. These hotspot
SNVs were covered at an average depth of 1151×. To conﬁrm
that the VAFs estimated from the sequencing data are
accurate, we compared the VAFs obtained from sequencing with
those estimated from digital PCR (dPCR) and found that they
have high correlation, as shown in Fig. 2a and Supplementary
Data 4.
Variants in EGFR exemplify the importance of detecting low
VAF cases. In 40-50% of Asian patients and 10% of white patients
with non-small cell lung cancer (NSCLC), somatic mutations are
present in EGFR16. Treatment with EGFR- tyrosine kinase
inhibitors (TKI) such as erlotinib, geﬁtinib, and afatinib in those
patients have shown improved outcomes compared to conven-
tional chemotherapy, with a response rate of 50–75%17. However,
>50% of the cases, the patient will develop acquired resistance
within 1 or 2 years in the form of a second-site mutation, EGFR
T790M, in the EGFR kinase domain. For these patients,
osimertinib (AZD9291), an oral irreversible EGFR-TKI (third
generation EGFR-TKI), has been shown to be effective with
improved safety proﬁle18, and was approved in 2015 by the
US FDA. This makes the detection of this variant critical for
patients with T790M-mediated resistance to EGFR-TKI. In our
cohort, this variant was present in 113 cases, and 24% had VAF
of under 5%.
Furthermore, a study identiﬁed another acquired mutation
EGFR C797S that confers resistance to AZD929119. Successful
molecules for overcoming this mutation were reported, too20. In
our cohort, we identiﬁed eight lung cancer patients with EGFR
C797S mutation occurring in cis with EGFR T790M mutation
(Fig. 2b–e and Supplementary Fig. 2); in one patient, serial
sampling conﬁrmed that the EGFR C797S mutation occurred
after the AZD9291 therapy (Fig. 2e). Since EGFR C797S appears
as an acquired resistance to target therapy, its VAFs were even
lower than that of EGFR T790M mutation or EGFR activating
mutations in the 8 samples, with the four cases having VAF of
1.4, 2.2, 3.9, and 4.0% (Fig. 2b). These ﬁndings highlight the need
for a platform with high sensitivity for low VAF variants.
These examples hint at the possibility that the VAFs in post-
chemotherapy samples may be lower in general. To determine
whether this is the case, we were able to classify 1557 samples as
pre- or post-treatment (1203 vs 354, respectively) based on
clinical chart review (Supplementary Data 2). We ﬁnd that the
overall VAF distributions of hotspot mutations tend to be a little
lower in the post-treatment samples but do not reach statistical
signiﬁcance (Supplementary Fig. 3). Similarly, tumor purity
also did not show statistically signiﬁcant difference between the
pre- and post-treatment samples. In some speciﬁc cases, e.g., in
the post EGFR-TKI therapy samples, we expect to ﬁnd tumor
resistance-inducing clones containing secondary mutations after
treatment. In the 141 lung cancer cases divided into pre- (n= 31)
and post- (n= 110) EGFR-TKI therapy, we found that the
VAF distributions at the hotspots were signiﬁcantly different
(P= 0.018), mostly due to EGFR T790M (Fig. 2f). The mutation
counts, at least as represented on the capture target area
(CancerSCAN V2 panel only), did not display consistent change
between pre- and post-treatment in the several cancer types
(Supplementary Fig. 4).
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Determining sufﬁcient sequencing coverage. For a test based on
high-throughput sequencing to be adopted in clinical practice, the
sensitivity and speciﬁcity of the test must be at least on par with
the currently available single-gene based tests. In conventional
molecular tests in the clinic, a standard metric for the perfor-
mance of a test is the limit-of-detection (LOD), the lowest con-
centration of an analyte that can be detected reliably (typically
deﬁned as having 95% sensitivity)21. A guideline by the American
College of Medical Genetics and Genomics for next-generation
sequencing-based assays does not recommend a speciﬁc coverage
threshold because the sensitivity and speciﬁcity depend on several
aspects of the assay and platform (e.g., base -call error rates, allelic
bias, presence of duplicate reads, and the performance of the
analytical pipeline). However, it recommends that a laboratory
should note the percentage of bases that reach the desired
minimum coverage in the target region, and recognizes the
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Fig. 2 Features of actionable mutations with low VAF. a Concordance between VAFs estimated from panels and dPCRs for low VAF variants. The Pearson
correlation coefﬁcient based on 59 actionable variants is 0.86. Variants with higher coverage (colors correspond to sequencing depths) tend to show
higher correlation; also see Supplementary Data 4. b Differences in VAF distributions among EGFR mutations in eight refractory lung cancer samples
harboring EGFR C797S. All samples had an activating mutation (EGFR exon19 non-frameshift (NFS) deletion or L858R) and two resistance mutations (EGFR
T790M and C797S), with the latter occurring at lower VAF. Dotted lines indicate mutations belonging to the same sample. The P-values were calculated
using the paired t-test. c, d Browser view of the case in which EGFR C797S occurred in cis with EGFR T790M (only a subset of the reads are shown). e An
acquired EGFR C797S mutation is found after AZD9291 therapy. f Comparison of VAF of EGFR variants of lung cancer samples (n= 141) pre- and post-
EGFR-TKI therapy (afatinib, erlotinib, or geﬁtinib). The P values were calculated using the Wilcoxon rank sum test
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importance of each laboratory determining the lower LOD of
variants based on dilution assays22.
To determine LOD for our panel-based test, we examined the
sensitivity of detection for a somatic SNV of given VAF as a
function of sequencing depth, using both simulated and
experimental data (Methods section). The simulation results
using the well-annotated variants in the HapMap sample
NA12878 show that depth of coverage needed to maintain a
given sensitivity increases greatly as VAF decreases (Fig. 3a). For
a 95% sensitivity and>95% positive predictive value (PPV; the
fraction of true variants among all called variants), ~ 40× is
needed for variants with 20% VAF, ~ 94× is needed for variants
with 10% VAF, but ~ 294× is needed for 5% VAF and ~ 1085× is
needed for 2% VAF. One reason for the high coverage needed
(e.g., ~ 1000× for a 2% variant means ~ 20 reads containing the
variant on average) is the high speciﬁcity required for this assay as
well as our accounting of the sampling error (i.e., a true 2% VAF
variant is present at variable percentages centered at 2%).
We also performed a re-sampling experiment with patient data
as another way of examining the impact of sequencing depth on
the detection rate. For the EGFR T790M mutation, present in 72
patients without EGFR ampliﬁcation (Supplementary Data 5),
subsampling from the real data shows that the average detection
rate of EGFR T790M (assuming that all mutations have been
detected in our ~ 1500× data at this position) is 84% at 200×,
74% at 100×, and 62% at 50× (Fig. 3b). These results suggest that
whole-exome sequencing, which typically has 100-200× coverage,
may miss 15–30% of this actionable mutation.
In a typical variant report based on panel-based assays,
the average coverage is given but not LODs for each gene or
each position. Without an LOD, when a variant is not called at a
given position, it is difﬁcult to distinguish between the true
absence of the variant and the lack of statistical power to detect
one. Despite improvements in the target capture step, the
coverage across a target region remains uneven for most
platforms (Supplementary Fig. 5). Indeed, a recent paper showed
the counter-intuitive result that WGS could be more powerful
than exomes for detecting exonic variants, with 3% of variants
detected on WGS missed on exomes due to uneven coverage. We
thus advocate annotating LOD at the gene or the nucleotide level,
at least for clinically-relevant mutations. One possibility is to do it
graphically, denoting LOD using the background color (Supple-
mentary Fig. 6 and Supplementary Data 6), but there may be
other ways to incorporate this information. Importantly, we
espouse the use of LOD as the more useful metric than
sequencing depth alone, since LOD incorporates additional
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information on the quality of the data and the characteristics of
the analytical pipeline.
Impact of tumor purity. The issue of what constitutes sufﬁcient
sequencing depth is inﬂuenced by other characteristics of the
patient sample, including tumor purity and the clonality of the
mutations, as well as the tissue preparation method and the
platform used. Lower tumor purity proportionally reduces the
effective coverage of the variant alleles in tumor cells, reducing
detection sensitivity. Importantly, whereas research projects may
impose a minimum threshold for tumor purity at the sample
selection stage, there is little control over tumor purity in the
clinic. In particular, many clinical specimens are derived from
biopsies rather than surgical resections, and the tumor purity in
such cases may be very low.
Although purity is difﬁcult to estimate from panel data, we
were able to obtain estimates in about half of the cases (Methods
section). The distributions of purity estimates for our samples and
the TCGA samples23 showed a striking difference (Fig. 4a). As an
additional piece of evidence, in ~3600 lung biopsy specimens
from a separate study we conducted, the histological purity
estimates are ≤20% in 30% and ≤40% in 51% of the cases
(Fig. 4b)24.
Furthermore, intra-tumor heterogeneity can result in addi-
tional variability that necessitates higher coverage. For example,
even if the mutation is present in 10% in the entire tumor, the
VAF of the biopsied portion may only be 2% due to spatial
heterogeneity. Another challenging aspect of working with
clinical samples is that they are often formalin-ﬁxed parafﬁn-
embedded (FFPE) tissues with degraded DNA and smaller
fragment sizes25. As a result, the effective coverage of an FFPE
sample after removing duplicate reads is substantially lower than
the target coverage (~800× vs ~1,000× in our data). There is,
however, a signiﬁcant gene-to-gene variation, with the coverage at
some genes higher in FFPE samples than in fresh frozen samples
(Supplementary Fig. 7).
Frequency of alterations at actionable mutations. Across the
5095 cases, the genes most frequently altered with actionable
mutations are shown in Fig. 5a, starting with KRAS (13%), EGFR
(9.5%), PIK3CA (9.4%), and ERBB2 (7.5%). In addition to SNVs,
we detected copy number variations (CNVs) and common
fusions using custom algorithms (Methods section). Overall,
SNVs/indels accounted for 62% of the detected variants while
CNVs and fusions accounted for 34% and 4%, respectively,
spread across multiple tumor types (Fig. 5b). About 44% of the
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patients had “actionable” alterations, i.e., the choice of treatment
regimen was based at least in part on the presence of the mutation
(Fig. 5c and Supplementary Fig. 8). In another 51%, the observed
mutation was present in the Catalogue of Somatic Mutations in
Cancer (COSMIC) but no treatment was available at present.
These numbers suggest the panel-based testing for cancer patients
is informative for nearly half the patients tested and that the
number of will continue to increase as more drugs become
available. These estimates are similar to the numbers reported in
other studies26.
Clinical relevance of low VAF variants. In primary tumors, a
‘driver’ mutation is expected to have a relatively high VAF due to
their occurrence early in carcinogenesis and the selective advan-
tage conferred by the mutation; in refractory tumors, however, a
secondary driver mutation that arises in response to a treatment
may be present with a low VAF27,28, as we showed above. To
illustrate the importance of such mutations in patient care, we
describe two examples of refractory cancer patients who had
clinical response to targeted therapy selected based on a low VAF
mutation.
The ﬁrst case is a 59-year-old never-smoker female with
NSCLC with multiple distant metastasis including bone and liver
(Fig. 5d). She underwent a lobectomy, but the cancer recurred; in
spite of palliative therapy (conventional chemotherapy, EGFR
targeted therapy, and radiotherapy), her cancer progressed slowly
for 5 years. When her condition worsened, she underwent a
transthoracic needle aspiration biopsy. Genomic proﬁling of the
biopsied specimen revealed EGFR L858R (29%) and T790M
(3.5%). The patient was subsequently enrolled with an AZD9291
trial and achieved partial remission. The second case is a 70-year-
old female patient with metastatic gastric cancer with peritoneal
seeding (Supplementary Fig. 9). After failing 8 cycles of
capecitabine/oxaliplatin chemotherapy, she underwent an eso-
phagogastroduodenoscopy biopsy. Genomic proﬁling of the
biopsied tissue revealed a PIK3CA E542K with 4.1% VAF, which
was conﬁrmed by dPCR (Supplementary Data 4). As a result, the
patient was treated with an AKT inhibitor and has achieved
partial remission, although the response was not durable.
Another approach to probe clinical relevance of low VAF
variants is to compare survival data of patients with low vs high
VAF variants who receive targeted therapy. If the low VAF
variants are as important as the high VAF ones, we expect to see
little difference in the survival curves; on the other hand, if the
low VAF variants are not informative, we expect to see signiﬁcant
differences. Examining lung cancer patients (n= 65) with EGFR
T790M who received 3rd generation EGFR-TKI, we ﬁnd that the
Kaplan-Meier curves for progression-free survival do not show
signiﬁcant differences between the low VAF cases (≤5%) and the
high VAF cases (>5%) (Fig. 5e). To show that this result does not
depend on the speciﬁc threshold for deﬁning “low” vs “high”
allele fraction, we also tried all possible subdivision into two
groups and computed the log-rank test in each case. We observed
that none of the P values were signiﬁcant (Supplementary
Fig. 10).
Discussion
Our analysis of 5,095 clinical samples demonstrates that a sig-
niﬁcant portion of clinically-relevant mutations are present at
lower VAFs than some may have assumed. There are two primary
factors for the lower VAFs. First, a substantial fraction of our
cohort comprised refractory cases that had treatment-induced
secondary mutations, which are more likely to have lower VAFs.
Second, the estimated tumor purities in our samples were fre-
quently low, causing the observed VAFs to be decreased by the
same percentage. It is noteworthy that the clinical specimens
obtained at our hospital were mainly from small biopsy specimen,
so had generally lower tumor purity than those observed in
TCGA samples, which were collected from operation specimen
for multi-dimensional proﬁling (DNA sequencing, RNA-seq,
SNP arrays, DNA methylation, proteomics, etc.). Given that
TCGA data have been used for developing and testing many
algorithms for estimating purity and somatic variant calling,
those algorithms may not be optimally tuned for some small-
sized clinical samples or damaged FFPE DNA.
The presence of many low VAF mutations has implications for
platform design. Targeted sequencing allows for the most sensi-
tive characterization of SNVs/indels in a subset of genes, but
cannot detect other variants such as gene fusions unless there are
speciﬁcally targeted with additional probes (we showed that it is
at times possible to identify translocations when discordant or
split reads are pulled down in the capture step29, but the sensi-
tivity is too low in general). With our CancerSCAN V2 panel
data, we have found that purity estimation was possible for about
half of the samples in which the target regions included multiple
CNVs and tumor purity was not too low. Our previous com-
parison of exome CNV identiﬁcation algorithms revealed highly
discordant result among six popular algorithms30; however, we
were able to call CNVs reliably whenever the magnitude of the
CNV was large and the purity was not too low. WGS allows for
less sensitive characterization of SNVs but across the entire
genome, including non-coding regions, and it can be used to
accurately identify copy number variants and various rearrange-
ments with nucleotide resolution. With an increasing amount of
available functional genomics and epigenomics data, we are
starting to recognize the role of some non-coding variants, e.g.,
mutations in enhancers that mediate the activity of tumor sup-
pressor or oncogenes31. Nonetheless, our results make it clear that
very high-depth sequencing on a custom panel should be the ﬁrst
assay in the clinic, with ﬂexibility to modify the targeted list as
new drugs become available through clinical trials for speciﬁc
mutations. Indeed, it appears that even exome sequencing, typi-
cally at 100–200×, would not have sufﬁcient sensitivity unless the
coverage is increased several-fold.
One limitation of this study is that our analysis was focused on
mutational hotspots. When low VAF mutations are observed at
other sites, it becomes more difﬁcult to determine whether they
are true mutations or are artifacts due to misalignment, sequen-
cing error, or extraneous biological sources (e.g., oxidative
damage or formalin ﬁxation in sample preparation). To remove
such artifacts, one needs a sophisticated variant calling method
that retains high speciﬁcity even for low VAF cases. Random
sequencing errors occurring at the same nucleotide position in
multiple reads is vanishingly small, and we should be able to
identify some variants even with 3 or 4 reads (at 1000×, 0.3–0.4%)
if there are appropriate ﬁlters to remove less conﬁdent cases13.
Other technical artifacts, e.g., due to read mis-alignment, can be
avoided by annotating alignment error-prone regions from a
large set of panel data. FFPE-induced mutations and other bio-
logical artifacts are more challenging to distinguish, as there are
currently no high-resolution models to predict where such
mutations are likely to arise at a given location.
There are several other challenges in panel sequencing. A
recent paper on the effect of tumor sequencing without the
matched normal suggested that up to a third of actionable
changes might be incorrectly classiﬁed as somatic when they are
actually germline32. With high-depth sequencing, the estimated
VAF will have a small error bar and the deviation from the
expected 0.5 for germline variants will be easier to discriminate.
Nonetheless, a large database of germline variants33 including
those from various ethnicities would be important to avoid
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misclassiﬁcation of germline as somatic variants. Improvements
in these areas, along with very high-depth sequencing and care-
fully tuned analysis pipeline including annotation of LOD, will
help deliver accurate mutational proﬁling data to help clinicians
make optimal therapeutic decisions.
Methods
Study design. Cancer patient samples were obtained at Samsung Medical Center
from January 2014 to August 2016 (Supplementary Data 2) with informed consent
from some patients and consent waived by the Institutional Review Board (IRB) for
other patients. The IRB of Samsung Medical Center (SMC) approved this study. A
pathologist examined each sample for diagnosis and tumor content. The inclusion
criteria for specimens in this study are (i) the possibility that the patient could be
enrolled in a clinical trial if an actionable mutation is discovered; and (ii) the
patient’s specimen was stored the pathology department with a sufﬁcient amount
of tumor fraction. Samples were typically processed without a paired normal tissue.
DNA extraction and library preparation and sequencing. Genomic DNA was
extracted from fresh tissues using QIAamp DNA mini kits (Qiagen, Valencia, CA,
USA) and from FFPE tissues using either a Promega Maxwell 16 CSC DNA FFPE
kit or a QIAamp DNA FFPE Tissue kit. DNA concentration and purity were
checked using a Nanodrop 8000 UV-Vis spectrometer (Thermo Scientiﬁc, Wal-
tham, MA, USA) and Qubit 2.0 Fluorometer (Life Technologies, Grand Island, NY,
USA). The degree of DNA degradation was measured using a 200 TapeStation
Instrument (Agilent Technologies, Santa Clara, CA, USA) and real-time PCR
(Agilent Technologies). Genomic DNA was sheared using a Covaris S220 (Covaris,
Woburn, MA). Target capture was performed using the SureSelect XT Reagent Kit,
HSQ (Agilent Technologies) and a paired-end sequencing library was constructed
with a barcode. After checking for library quality, sequencing was performed on a
HiSeq 2500 with 100-bp reads (Illumina, San Diego, CA, USA). For exome
sequencing, SureSelect XT Human All Exon v5 was used for target capture; for
whole-genome sequencing, the TruSeq Nano DNA Sample prep kit was used
(Illumina).
Panel design and sequencing. Samples were proﬁled on CancerSCAN, a targeted-
sequencing platform designed at Samsung Medical Center. This customized plat-
form offered ﬂexibility to include target genes curated from the literature of
requested by the researchers and clinicians. These selected genes covered variants
associated with the targeted cancer therapies (i) approved by the Korean MFDS
and US FDA, (ii) in the clinical trials at the Precision Oncology Clinic at Samsung
Medical Center or (iii) reported as having association with response of therapy in
the public databases and the literature.
Using both existing and new algorithms (see below), we detected SNVs, small
indels, CNVs, and gene fusions (see below). 1497 patients were proﬁled on
CancerSCAN V1, which targeted 83 genes; the rest were proﬁled on Version 2,
which targeted 381 genes. TERT promoter was also included. The genes contained
in the two versions are listed in Supplementary Data 1.
Purity estimation. Computational inference of tumor purity from panel data is
more difﬁcult than from exome or whole-genome data since the limited set of
genes is less likely to contain genomic alterations, which are informative for
making inferences on tumor purity. First, we identify copy-neutral regions. The
minor allele frequencies at known SNPs in the copy-neutral regions are near half
and, when only those SNPs are considered, their read densities correspond to the
most prominent peak in the distribution of read coverage at the SNPs, based on the
hypothesis that pure polyploidy tumors with 4N in all chromosomes are extremely
rare. The regions of copy number gain and loss are identiﬁed by their adjusted
coverage relative to the copy number-neutral regions. Once the copy-neutral, gain,
and loss regions are delineated, the following formula can be used to infer the
proportion of each tumor clone:
Alternative allele frequency ¼ P  Y þ 1 Pð Þ
P  X þ 2 1 Pð Þ ;
where X and Y are the numbers of all and alternative alleles at each group of
clustered SNPs in the tumor, respectively, and P is a proportion of tumor clone
ranging from 0 to 1. Tumor purity was inferred from the maximum value among
the Ps estimated at multiple positions, with the hypothesis that the largest clone
best represents tumor purity. Tumor purity below 30% was less reliable and was
not annotated. More details will be available in a separate manuscript in
preparation.
Variant detection. Alignment: The paired-end reads were aligned to the human
reference genome (hg19) using BWA-MEM (v.0.7.5). SAMTOOLS (v0.1.18),
GATK (v3.1-1), and Picard (v1.93) were used for ﬁle handling, local realignment,
and removal of duplicate reads, respectively. We recalibrated base quality scores
using GATK BaseRecalibrator based on known single-nucleotide polymorphisms
(SNPs) and indels from dbSNP138.
SNV detection: To increase sensitivity, we used two published methods for SNV
detection, MuTect13 (v1.1.4) and LoFreq14 (v0.6.1), with default parameters. The
union of the variants identiﬁed by the two callers (with the high conﬁdence (HC)
set for MuTect) was used as the candidate set of variants. The number of false
positives for the simulated cases in Fig. 3a is small, as shown in the estimated PPV
curves (Supplementary Fig. 11a). Small indels were identiﬁed by Pindel34 (v0.2.4)
with its default setting. We applied several ﬁltering steps to ﬁlter these putative
germline variants: (i) variants with very high VAF (≥97%), except for the hotspot
mutations; (ii) variants with population allele frequency >3% in the >400 normal
samples in our database (this is important for removing ethnic-speciﬁc variants);
and (iii) other frequently detected variants that are likely to be alignment artifacts
or are in hard-to-sequence regions, as curated by manual review and compiled in
our database. The variants were annotated by ANNOVAR35.
We could improve the PPV of our SNV calling pipeline by an additional
ﬁltering step. MuTect already implements several steps for removing likely false
positives, using features that are often characteristic of false positives such as
proximity of an indel, multiple mutations in a small neighborhood, strand bias, and
clustered read start/end positions. Brieﬂy, our additional step implements a logistic
regression model based on the factors mentioned above and trained it based on low
VAF variants that arise in normal samples (in particular, a subset that has an
abnormally high transition or transversion rate at each position, as they are likely
to be enriched for false positives). We used 38 normal samples (28 normal tissues
(Supplementary Data 2) and 10 normal HapMap cell lines (Supplementary
Table 1)) proﬁled on the panel to train the classiﬁer. We checked performance of
the model by cross-validation and selected the parameter of the regression model
by receiver operating characteristic (ROC) analysis of NA12878. When this model
was applied to NA12878 (for which we have a well-validated true positive calls), we
found that the number of false positives was substantially reduced (Supplementary
Fig. 11 and Supplementary Data 7).
CNV detection: To identify somatic CNVs, we calculate the mean read depth at
each exon, normalized by the coverage of the target regions in that sample. This
normalized read depth is further standardized by dividing by the expected coverage
for a normal individual (The expected coverage at each exon was taken to be the
median of the read depth at that exon across a set of normal individuals). These
steps account for the variability in capture efﬁciency and GC content at different
exons. To infer the correct copy number, the amplitude of the copy numbers were
then adjusted based on the estimated purity. If the adjusted amplitude of the copy
change is greater than 1 or less than 1 (in log scale), the region is called as
ampliﬁcation or deletion, respectively.
Fusion detection: Most fusions involve intronic breakpoints. To identify fusion
using a gene panel, we tiled across the “hotspot” introns that are known to contain
most breakpoints for a set of clinically relevant fusions. In version 2, introns of 22
genes were covered densely with capture probes. Since the average DNA fragment
size was ~180 bp in our libraries (thus, with 100 bp reads, most fragments are fully
sequenced), we expect each fusion to be reﬂected in multiple split reads. We require
four split reads to make a fusion call, with at least two reads mapping to each side
of the breakpoint. We also consider both primary and secondary alignments to
increase sensitivity. Once the candidate fusions are identiﬁed, further ﬁltering is
performed using various features including mapping quality, insert size, CIGAR
string, strand direction, alignment information, local cluster coverage, and
concordance of the read alignment direction. The split reads allow mapping of the
breakpoints with base pair resolution.
Limit of detection estimation by manual dilution assay. In conventional
molecular tests, detection capability is typically speciﬁed in terms of LOD, fol-
lowing the guidelines established by The Clinical and Laboratory Standards
Institute (CLSI), an international organization that develops clinical and laboratory
practices21. American College of Medical Genetics and Genomics (ACMG)
guideline for NGS also recommends that the lower LOD should be determined for
variant detection based on dilution assays22. For a given sequencing depth, LOD,
the lowest concentration that can be consistently detected with ≥95% sensitivity, is
computed by (i) estimating sensitivity of detection at dilutions (in this case, variant
allele fraction); and (ii) ﬁtting a probit regression model to the data, which then
allows estimation the sequencing depth at which the sensitivity is 95%. (Probit
regression is a linear regression model for a binary response variable and is similar
to logistic regression except that the link function is the cumulative normal dis-
tribution function instead of logit).
We implemented a manual dilution assay, adopting the scheme used in
Frampton et al.36 Puriﬁed DNA of 10 HapMap cell lines (Supplementary Table 1)
were obtained from Coriell Institute and were mixed in equal proportions. Each
cell line and the mixed pool were sequenced using the CancerSCAN V2 panel.
After SNPs were called for individual cell lines by both MuTect and LoFreq, more
than ~1700 reliable exonic SNPs (those with a refSNP number) were identiﬁed,
with a wide range of VAFs starting with ~5%, which corresponds to a unique
heterozygous SNP in one cell line. Once the variants were called at these positions
in the mixed pool, we could deﬁne true positives and false negatives as the variants
detected and undetected, respectively, at various VAFs. To generate more data
points at each VAF, we also down-sampled the pool at various fractions. These
points were then used to construct the regression line and estimate the LOD at each
VAF (Supplementary Fig. 12).
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Limit of detection estimation by in silico dilution assay. In a manual dilution
assay described above, the true concentration of each cell line in the mixed pool
maybe different from the intended 10%. The deviation may arise due to inaccurate
DNA quantitation and/or pipetting error, with greater deviation at low con-
centrations37. To avoid this problem, we also performed in silico dilution assay,
using the well-characterized NA12878 cell line38 sequenced on the CancerSCAN
V2 panel.
We selected all heterozygous SNPs (n= 222) that have “high-conﬁdence”
genotype calls (version 2.19) and are in the target exonic region of the panel
(Supplementary Fig. 13). To simulate various diluted VAFs at these heterozygous
SNPs, we randomly selected reads containing variant alleles and replaced some of
them with the reference bases, controlling the dilution level by the probability that
the selected variant base will be converted, as illustrated in Supplementary Fig. 14.
After a wide range of VAFs were obtained at the SNP positions, we followed the
same procedure as in the manual assay to estimate LOD. This in silico approach
resulted in similar sensitivity lines as in the manual assay, except that they were
more stable for lower VAFs. Figure 3a is generated from this analysis.
Performance comparison of SNV callers. To set up an accurate SNV pipeline,
we compared the performance of four callers (LoFreq, MuTect, Platypus39, and
VarDict40) and their combinations with default and modiﬁed parameters on
332 exonic SNPs (both heterozygous and homozygous SNPs in the target region)
of NA12878 (Supplementary Data 7). The results involving LoFreq, MuTect, and
their combinations on the in silico dilution data are shown in Supplementary
Fig. 11.
Digital PCR. Digital PCR was performed on the QX200 ddPCR™ System (Bio-Rad)
to validate low VAF (2.5–10.3%) variants in 59 samples (Supplementary Data 4).
ddPCR reaction mixes were prepared with template gDNAs, ddPCR Supermix
(Bio-Rad) and TaqMan primer-probe mixtures, and partitioned into oil droplets
(~20,000) generated by the QX200 droplet generator. The droplets were then
thermal-cycled using Veriti 96-Well Thermal Cycler (Life Technologies). Ampliﬁed
droplets were imaged on the QX200 droplet reader (Bio-Rad), and analyzed by
QuantaSoft™ software (Bio-Rad). The concentration of the nucleic acid sequence
targeted by the FAM and VIC or FAM and HEX dye labeled probes was estimated
using Poisson distribution.
Classiﬁcation of variants. We classiﬁed all variants into three tiers (Supple-
mentary Table 2). Tier 1 variants included the variants that were listed as ther-
apeutic targets by the Korean MFDS or the US FDA as well as those that have been
reported to be candidates for clinical trials (Supplementary Data 8). Both Can-
cerSCAN V1 and V2 panels covered all positions of the tier 1 variants. Tier 2
variants included any mutation that was reported in COSMIC (version 64). For
gene fusions, those involving a target gene and a known partner (in COSMIC) as
Tier 1 and a novel partner as Tier 2. Tier 3 variants included all other mutations.
“Actionable” variants in Fig. 5c are Tier 1 variants; “known” (but not actionable)
alterations are Tier 2 variants. Most of our analysis deals only with the actionable
(tier 1) variants that were in both versions. Some ﬁgures (Fig. 5c, Supplementary
Fig. 4, and Supplementary Fig. 8) only include CancerSCAN V2 patients for a fair
comparison of non-actionable proportions.
Data availability. The data that support the ﬁndings of this study are available on
request from the corresponding author (W.-Y.P.). The raw data are not publicly
available due retroactively collected samples not having explicit consent for sharing
of raw data.
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